Fruquintinib for advanced colorectal cancer after standard treatments
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new pill, fruquintinib, for people with advanced colorectal cancer that has not responded to or stopped responding to standard chemotherapy. It aims to control the cancer and may offer a new option when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older and can swallow pills.
- You have been diagnosed with metastatic or recurrent colorectal cancer and have had two prior chemotherapy treatments (first-line and second-line).
- You are generally able to take care of yourself (ECOG performance status 0 or 1) and expected to live at least 3 months.
- Your blood counts, kidney, liver, and heart function are within acceptable levels (e.g., hemoglobin > 9 g/dL, creatinine clearance > 30 mL/min, total bilirubin ≤ 2× ULN, QTc ≤ 480 ms).
- You are not pregnant, breastfeeding, and agree to use effective contraception during and for 4 weeks after the trial.
- You do not have uncontrolled infections, major bleeding risk, or other serious health conditions that could make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.